🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Authors
Daniel Schmolze

Daniel Schmolze

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer”.

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer

Cancer Immunology Immunotherapy(2023)10.1007/s00262-023-03470-y

N/A

0.809DataRank · unranked

22 citations

Weihua Guo, Susan E. Yost, Xuan Ge, Jin Sun Lee, Paul Frankel +12 more

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer

The Oncologist(2023)10.1093/oncolo/oyad026

N/A

0.580DataRank · unranked

14 citations

Susan E. Yost, Yujie Cui, Christopher Ruel, Mireya Murga, Aileen Tang +10 more

Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis

PLoS ONE(2020)10.1371/journal.pone.0229955

N/A

0DataRank · unranked

33 citations

Susan E. Yost, Paul Frankel, Andrew Dagis, Yu Cao, Roger Wang +8 more

Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study

Cancer Cell(2023)10.1016/j.ccell.2023.08.002

N/A

0DataRank · unranked

254 citations

Daniel Reisenbüchler, Nicholas P. West, Jan Niehues, Jiefu Zhu, Sebastian Foersch +62 more

937 Comprehensive immune profiling unravels evolution of spatial distribution and immune repertoire in tumor microenvironment from primary to metastatic triple negative breast cancers

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0937

N/A

0DataRank · unranked

0 citations

Colt A. Egelston, Katherine E. Hutchinson, Jennifer M. Giltnane, Veronica Ibarra, Bonnie Liu +4 more

Spatially distinct cellular and molecular landscapes define prognosis in triple-negative breast cancer

Cell Reports(2025)10.1016/j.celrep.2025.116752

N/A

0DataRank · unranked

3 citations

Darya Veraksa, David Frankhouser, Lixin Yang, Jerneja Tomšič, Raju Pillai +11 more

Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer

The Oncologist(2020)10.1002/onco.13574

N/A

0DataRank · unranked

43 citations

Jin Sun Lee, Susan E. Yost, Sierra Min Li, Paul Frankel, Christopher Ruel +17 more

Trop-2 expression as a biomarker of response to sacituzumab govitecan in patients with HER2-negative metastatic breast cancer: A pilot study

Cancer Treatment and Research Communications(2025)10.1016/j.ctarc.2025.100954

N/A

0DataRank · unranked

2 citations

Megan Wong, Nora Ruel, Daniel Schmolze, Min Han, Joanne Mortimer +2 more

Towards integration of 64Cu-DOTA-trastuzumab PET-CT and MRI with mathematical modeling to predict response to neoadjuvant therapy in HER2 + breast cancer

Scientific Reports(2020)10.1038/s41598-020-77397-0

N/A

0DataRank · unranked

37 citations

David A. Hormuth, Vikram Adhikarla, Prativa Sahoo, Daniel Abler, Lusine Tumyan +5 more